Santaris to Present Phase IIa Data on HCV Drug
April 19, 2012
Santaris to Present Phase IIa Data on HCV Drug
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- With Positive Phase II Data on HCV Drug, Santaris Aims for Another Clinical Trial by the Summer
April 26, 2012 / Gene Silencing News - UNC Teams Uncovers How HCV Uses miR-122 to Survive
January 5, 2012 / Gene Silencing News - Santaris Presents Phase IIa Data on microRNA-Targeting HCV Drug
November 10, 2011 / Gene Silencing News - Santaris Releases Phase II Data Showing Its HCV Drug Is Well Tolerated, Effective
October 6, 2011 / Gene Silencing News - Santaris Nears End of Phase II Trial of miRNA HCV Rx, Seeks Partnership Since GSK Opted Out
September 15, 2011 / Gene Silencing News